• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Treatment >Rituximab: A Hope for Lymphoma Patients
【24h】

Rituximab: A Hope for Lymphoma Patients

机译：利妥昔单抗：淋巴瘤患者的希望

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rituximab is an antibody targeting the CD20 receptor protein of B-cells, the immune cell responsible for specific adaptive immune system properties. In B-cell lymphomas, where the B-cell lymphatic cells underlie the lymphoma phenotype, the use of rituximab to specifically target and destroy B-cells is a relatively recent strategy for treating lymphomas. Indeed, even recently it has been determined that classic Hodgkin’s lymphoma can be treated by a special regimen of rituximab. Rituximab had such a pronounced effect on the survival rates of certain lymphomas that the survival outcomes have fundamentally changed. These outcomes have changed to the degree that prognostic tools used to infer survival rates have had to be overhauled. The exact molecular mechanisms of rituximab activity had recently been elucidated, and although heterogeneity in lymphoma response to rituximab exists, detailed molecular studies investigating this have as a result uncovered new molecular targets, such as CD55 and CD59. The above mentioned topics, as well as the toxicity of rituximab, the use of rituximab with supplemental treatments in parallel such as histone deacetylase inhibitors, radiation therapy, and the effects of rituximab on different types of lymphomas, are all reviewed here.
机译：利妥昔单抗是靶向B细胞CD20受体蛋白的抗体，B细胞是负责特异性适应性免疫系统特性的免疫细胞。在B细胞淋巴瘤是B细胞表型的基础的B细胞淋巴瘤中，使用利妥昔单抗特异性靶向和破坏B细胞是治疗淋巴瘤的相对较新的策略。确实，甚至在最近，已经确定经典的霍奇金淋巴瘤可以通过利妥昔单抗的特殊疗法治疗。利妥昔单抗对某些淋巴瘤的存活率有如此显着的影响，以至于生存结果发生了根本变化。这些结果已经改变到一定程度，必须改写用于推断生存率的预后工具。最近已经阐明了利妥昔单抗活性的确切分子机制，尽管存在淋巴瘤对利妥昔单抗反应的异质性，但详细的分子研究对此进行了研究，结果发现了新的分子靶标，例如CD55和CD59。本文对上述主题以及利妥昔单抗的毒性，利妥昔单抗与并行补充疗法（如组蛋白脱乙酰基酶抑制剂，放射疗法）以及利妥昔单抗对不同类型淋巴瘤的影响进行了综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号